Group by Stud Drug	ty name		tistics for		idy	Sam	ple size		Std	diff in me	ans and 951	6.01		-
		Std diff in means		Upper	p-Value	Baseline	Post intervention							Relative weight
	2015*	3.673		4.194	0.000	76	76	- T	1		1	1	k	20.92
	rews, 2021*	2.859		3.876	0.000	15 34	15 34				I .		3	17.86
	did. 2021*	3.452		4.202	0.000	26	26				I .	1 -	- 1	20.56
Drug Kuo	2021*	3.456		3.958	0.000	76	76				I .		>	21.01
Irug Poo Irug Prec	led liction Interva	2.931		3.898 6.608	0.000				-				3	
	2015	3.176		3,993	0.000	26	26							19.94
lacebo And	rews, 2021	-1.486		-0.677	0.000	15	15		- 1		I .		- 1	19.96
lacebo Cart lacebo Che	did, 2021	1.140		1.652	0.000 0.743	34 10	34 10						3	20.52
lacebo Kuo	2021	3.657		4.546	0.000	26	26						3	19.80
lacebo Poo		1.323		3.012	0.125								2	
lacebo Prec Iveral Poo	fiction Interva	1.323		7.918	0.000			-					1	
	fiction Interva		-1.345	6.414				- k-	-+-		<u> </u>	+-		
								-1.00	-0.50		.00	0.50	1.0	
									SHT4 agos	ist		Placebo		12=91.
							GCSI							
Group by	St	udy na	me		Stat	istics f	or each s	tudy		Std	diff in n	neans	and 95	% CI
Drug					d diff means	Lowe		p-Value						
Deve		ell. 202			11.818		2 12.723		1			Т.		
Drug													. 1	
Drug		ndrews,			1.848	0.99						17	-	
Drug		arbone, 2			3.684								-	
Drug		nedid, 20	021*		-0.069							+		
Drug		oled			4.313							+-	_	-
Drug	Pr	ediction	Interv	al	4.313	-19.36	31 27.986		- H			-	_	
Placebo	At	ell, 202	1		14.063	12.23	3 15.893	0.000			1			
Placebo	Ar	drews,	2021		2.522	1.56	3 3.481	0.000			1	1.	- 1	
Placebo	Ca	arbone, 2	2019		0.968	0.46	6 1.470	0.000				-		
Placebo	C	nedid. 20	021		0.000	-0.8	7 0.877	1.000			1	+		
Placebo	Po	oled			4.266	0.63	6 7.896	0.021				-		-
Placebo		ediction	Interv	al			7 21.908				L			
Overall		oled	in the little		4.283	1.3								
Overall		ediction	Intern		4.283		3 14.689							
Overail	FI	ediction	Interv	21	4.203	-0.14	.5 14.005		-10.0	. 7	5.00	0.00	5.0	
									-10.0		agonist		Plac	
										3114	ayonist		Flac	1 003
						Adv	erse ev	/ents						
Study name		stics for e		dy					Odds a	atio and	95% CI			
	ratio I	imit I				ention F				_			Rela	ght
Abell, 2021		0.430	1.466	0.46			38 / 59		1	-	- 1			9.39
			22.842	0.00			0/15	1	1		-+	_		7.18
			65.832	0.00			3/34		1			-		6.18
Kuo, 2021			21.615	0.00		/76	4/26	1	1		-	_	2	7.25
Pooled			46.684	0.04	5			1	1					
	6.975 0	0.001 399	30.639					k	+	+	-+	_	-	
Prediction Interval														
Prediction Interval								0.01	0.1	1	10		100	

Gastric Emptying

S670

Intermittent Colonic Exoperistalsis Reduced Suppositories and Oral Laxatives in Functionally Constipated Women With Slow Transit

Immaculada Herrero-Fresneda, PhD*.

MOWOOT, Esplugues de Llobregat, Catalonia, Spain.

[0669] Figure 1. Forest plot for studied outcomes.


Introduction: Female sex and increasing age are risk factors for constipation. Studies have found colon transit times to be longer in women. Constipation appears or worsens among perimenopausal women. After lifestyle changes, second-line treatment are laxatives. However, most laxative agents show limited efficacy for chronic use, especially in women with comorbid conditions or concomitant medication. Intermittent colonic exoperistalsis (ICE) is a non-invasive, non-drug treatment for chronic constipation. It has been developed to facilitate natural bowel movements and reduce the side effects of laxatives, enemas, or other invasive approaches. ICE has been proven safe and effective in constipation from both neurogenic or idiopathic aetiology in both men and women. Here, its use among women with functional chronic constipation was evaluated.

Methods: Adult women with chronic functional constipation and a previous diagnosis of slow transit were recruited in 4 hospitals in Germany. The treatment consisted of using the ICE medical device for 15 to 30min daily, at home. Patient outcomes were self-reported through anonymous, structured feedbacks collected at baseline (F1) and after some time under ICE treatment (F2).

Results: Data resulted from n=12 women (5 aged 18-39 yr, and 7 aged 40-60 yr). The mean time of ICE treatment at F2-feedback collection was 6,29(5,12) months (min 1; max 16). No one reported any serious adverse event. Three patients described occasional low self-remitting adverse events which did not affect the treatment compliance. Average fecal consistency increased from 2.00(1.13) to 3,75(1.91) in the Bristol scale; *P*=0.0084. Bowel movements increased in average by 2.65 per week; *P*=0.0037. Time spent per each bowel movement was reduced by 100.5 min, *P*=0.0199.Of 11 women using oral laxatives, 6(55%) had reduced its use, incl. 1(9%) that fully stopped; *P*=0.0272. Of 9 using suppositories, 8(89%) had reduced its use, incl. 6(67%) who stopped completely; *P*=0.0028. Of 6 using enemas, 3(50%) reduced its use, inc. 2 who fully stopped. In total, 73% (8/11) of women stopped or reduced so evacuation; *P*=0.0028 (Figure 1).

Conclusion: The amelioration in bowel function was accompanied by a notable reduction in aids to evacuation, with a high percentage of women stopping the use of suppositories. This in-use structured feedback points to the potencial of ICE substituting more invasive and drug approaches in bowel management strategies for functionally constipated adult women with slow transit.

The American Journal of GASTROENTEROLOGY



[0670] Figure 1. Columns represent, from left to right, the number of women (N, left axis) using Oral Laxatives (dark grey), Suppositories (grey) and Enemas (light grey), at baseline (F1) and at the moment of feedback, under treatment (F2). The decrease in N at F2 indicates the number of women fully stopping each aid to evacuation. Lines represent the mean±SD number of Bowel Movements per week (-o-; N, left axis) and the mean±SD time spent per evacuation (···∆···; min, right axis).

S671

Telehealth Is Effective in Delivering Pelvic Floor Physical Therapy in Patients with Pelvic Floor Disorders

Elisa Karhu, MD, MS^{1*}, Julia Barten, DPT², Gloria Yi, DPT², Yasir R. Rajwana, MD³, Brooke Gurland, MD⁴, Leila Neshatian, MD, MSc⁵.

¹Stanford University, Stanford, CA; ²Stanford Health Care, Redwood City, CA; ³Stanford Healthcare, Palo Alto, CA; ⁴Stanford University, Redwood City, CA; ⁵Stanford, Redwood City, CA.

Introduction: Pelvic floor physical therapy (PFPT) is recommended for management of pelvic floor disorders (PFD) including functional defecatory disorders and fecal incontinence. Telehealth utilization, largely spurred by COVID-19 pandemic, has become preferred due to convenience and access. We aimed to assess the effectiveness of telehealth for delivering PFPT.

Methods: In this IRB approved, cross-sectional study, 812 patients who had undergone PFPT by telemedicine or in combination with in-person visits were surveyed. Patient Global Impression of Change (PGIC) was used to analyze post intervention effectiveness (Table 1).

Results: Overall, 141 patients with PFD, 113 female, mean (SD) age of 52 (17) completed the study. The mean number of total encounters was 4.55 (4.25) with 2.81 (2.08) telehealth visits. A total of 42 (30%) patients reported no change/worse, 27 (19%) minimal improvement, and 72 (51%) moderate/much improvement of symptoms on PGIC survey. Number of visits did not impact response to therapy as reflected by PGIC score. Age was significantly different among groups. Mean (SD) age of patients with no improvement was 59 (15), minimal improvement 56 (16), and moderate/much improvement 47 (17) (P < 0.002). Gender, race, BMI, medical comorbidities, obstetric and pelvic surgical history, or symptoms did not influence response to therapy. Patients < 50 years old reported significantly greater degree of symptom improvement (P < 0.02), symptom resolution (P < 0.002), meeting personal goals (P < 0.0001), and improved pelvic floor muscle strength, coordination, and relaxation (P < 0.05). They also reported verail satisfaction with bowel movements, better control of bowel function, and less negative impact of bowel problems on quality of life (P < 0.005). Telehealth was preferred by 54 (38%) (64%) patients 115 (85%) felt that therapist was able to understand their symptoms and start them on a program 116 (83%) after the first visit, regardless of age, 89 (64%) patients preferred a combination of in-person and telehealth visits as compared to 42 (30%) patients who preferred only in-person visits.

Conclusion: Utilizing telehealth for PFPT appears to be effective and may increase access to care. Future research is needed to determine whether efficacy of telehealth interventions is influenced by challenges faced by older adults in effectively utilizing telehealth and to identify strategies to address barriers.

Table 1. Efficacy of telehealth for pelvic floor physical therapy by age

		All		AGE < 50		AGE > 50		
Questions	Response	N	%	N	%	N	%	P-value
Was a video visit your preference?	No Yes	86 54	61 39	38 27	58 42	48 27	64 36	0.502
After seeing your Physical Therapist via video, did you feel that they were able to understand your symptoms?	No Yes	21 115	15 85	6 58	9 91	15 57	21 79	0.065
Do you feel that your Physical Therapist was able to adequately help you understand pelvic floor anatomy via video visit?	No Yes	24 110	18 82	9 55	14 86	15 55	21 79	0.267
Do you feel that your Physical Therapist was able to get you started on home exercises to address your complaints after the first visit?	No Yes	23 116	17 83	9 57	14 86	14 59	19 81	0.380
How did your symptoms change during the course of care?	Worsen Same Better	9 49 81	6 35 58	3 16 46	5 25 71	6 33 35	8 45 47	0.019
Did you symptoms resolve during your course of care?	No Yes	114 27	81 19	46 20	70 30	68 7	91 9	0.002
Did you feel that your personal goals were met during your course of care?	No Yes	75 66	53 47	25 41	38 62	50 25	67 33	0.001
Would you recommend pelvic PT for others with similar issues?	In-person only Combined Telehealth & In-person Telehealth only No	42 89 2 6	30 64 1 4	16 46 2 2	24 70 3 3	26 43 0 4	36 59 0 5	0.189
Do you feel like you understand the relationship between your pelvic floor muscles, bladder, bowel, and/or sexual function?	Yes No	115 23	83 17	58 8	88 12	57 15	79 21	0.170
Do you feel like you understand proper coordination and control of pelvic floor muscles?	Yes No	106 35	75 25	50 16	76 24	56 19	75 25	0.881
Do you feel like your pelvic floor muscle awareness improved during your course of care?	Yes No	114 26	81 19	56 10	85 15	58 16	78 22	0.326
Do you feel like your pelvic floor muscle coordination improved during your course of care?	Yes No	88 53	62 38	47 19	71 29	41 34	55 45	0.043

© 2023 by The American College of Gastroenterology

The American Journal of GASTROENTEROLOGY

Copyright © 2023 by The American College of Gastroenterology. Unauthorized reproduction of this article is prohibited.